Skip Navigation


QJM Advance Access originally published online on January 20, 2006
QJM 2006 99(2):123-124; doi:10.1093/qjmed/hcl006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/2/123    most recent
hcl006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walshe, J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walshe, J.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Correspondence

Management of rare diseases

The first 10% of the full text of this article appears below.

Sir,

By some strange coincidence (I cannot believe it was editorial collusion) there are articles on rare and ultra-rare diseases in both the British Medical Journal1,2 and the concurrent QJM.3 All three articles raise the question of who, if any one, should pay for the medication of sufferers of such conditions. All take for granted that treatment for such diseases is very expensive and will take an unfair slice of the financial cake for health care. However, this is not necessarily true.

. . . [Full Text of this Article]

J.M. Walshe

Department of Neurology The Middlesex Hospital London


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?